<DOC>
	<DOC>NCT01924520</DOC>
	<brief_summary>A study was to evaluate the safety and plasma concentration changes of quetiapine after repeated administration of FK949E (extended-release formulation of quetiapine) in patients with major depressive disorder (MDD).</brief_summary>
	<brief_title>Oral Multiple-dose Study in Patients With Major Depressive Disorder</brief_title>
	<detailed_description>The objective of the study was to evaluate the safety and pharmacokinetics of multiple oral doses of FK949E (extended-release formulation of quetiapine) of three doses in patients with major depressive disorder (MDD).</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Diagnosis of major depressive disorder by the M.I.N.I. according to the DSMIVTR Female patients of childbearing potential with a negative serum pregnancy test result and who were willing and able to use a reliable method of birth control during the study. Patients who could understand and comply with the requirements of the study, as judged by the investigator/subinvestigator. A current or past history of a DSMIVTR Axis I disorder other than major depressive disorder within 6 months prior to provision of written informed consent. Diagnosis of a DSMIVTR Axis II disorder that was considered to have a major impact on the patient's current psychiatric status. A history of substance or alcohol abuse or dependence excluding caffeine and nicotine. Patients who were unable to abstain from drugs that induce or inhibit the drugmetabolizing enzyme CYP3A4 from 14 days prior to screening assessment and throughout the study period. Patients showing evidence or signs of renal or hepatic failure, serious heart disease, cerebrovascular disease, viral hepatitis B or C, or acquired immunodeficiency syndrome (AIDS) (carrier). Patients being treated for hypertension or patients with clinical finding that in the opinion of the investigator/subinvestigator could be negatively affected by the study or that would affect the study results (e.g., hypertension, unstable angina). Patients with concomitant hypotension or orthostatic hypotension (hypotension is defined as systolic blood pressure of less than 100 mmHg) Conditions that could affect absorption and metabolism of the study medication (e.g., malabsorption syndrome, liver disease) A current diagnosis of malignant tumor unless in remission for at least 5 years (except basal or squamous cell skin carcinoma). A history of transient ischemic attack (TIA). A history of seizure disorder, except for febrile convulsions Application of electroconvulsive therapy within 90 days prior to the start of study drug administration Use of a depot antipsychotic injection and inability to be off the drug for a period of twice the dosing interval prior to screening assessment and throughout the study period A score of â‰¥ 3 on the HAMD17 Item (suicide) or a suicide attempt within the past 6 months. Patients judged to be at serious suicidal or homicidal risk in the opinion of the investigator/subinvestigator.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Antipsychotic</keyword>
	<keyword>FK949E</keyword>
	<keyword>Quetiapine</keyword>
</DOC>